Cargando…
Selection of Biologics for Type 2–High Asthma
Autor principal: | Yilmaz, Insu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775871/ https://www.ncbi.nlm.nih.gov/pubmed/31106563 http://dx.doi.org/10.1164/rccm.201904-0763LE |
Ejemplares similares
-
The Visible and Invisible Faces of the Iceberg of Type 2 Asthma
por: Yılmaz, İnsu, et al.
Publicado: (2021) -
Reply to Yilmaz: Selection of Biologics for Type 2–High Asthma
por: McGregor, Mary Clare, et al.
Publicado: (2019) -
Eligibility of C-BIOPRED severe asthma cohort for type-2 biologic therapies
por: Deng, Zhenan, et al.
Publicado: (2023) -
Outcome of SARS-CoV-2 infection in patients with severe asthma on biologics
por: Kagohashi, Katsunori, et al.
Publicado: (2022) -
Disconnect for Tezepelumab on Exacerbations, Symptoms, and Quality of Life in Type 2 Low Asthma
por: Lipworth, Brian, et al.
Publicado: (2023)